Dopamine- or L-DOPA-induced neurotoxicity: The role of dopamine quinone formation and tyrosinase in a model of Parkinson’s disease

Dopamine (DA)- or L-dihydroxyphenylalanine- (L-DOPA-) induced neurotoxicity is thought to be involved not only in adverse reaction induced by longterm L-DOPA therapy but also in the pathogenesis of Parkinson's disease. Numerousin vitro andin vivo studies concerning DA- or L-DOPA-induced neurotoxicity have been reported in recent decades. The reactive oxygen or nitrogen species generated in the enzymatical oxidation or auto-oxidation of an excess amount of DA induce neuronal damage and/or apoptotic or non-apoptotic cell death; the DA-induced damage is prevented by various intrinsic and extrinsic antioxidants. DA and its metabolites containing two hydroxyl residues exert cytotoxicity in dopaminergic neuronal cells mainly due to the generation of highly reactive DA and DOPA quinones which are dopaminergic neuron-specific cytotoxic molecules. DA and DOPA quinones may irreversibly alter protein function through the formation of 5-cysteinyl-catechols on the proteins. For example, the formation of DA quinone-α-synuclein consequently increases cytotoxic protofibrils and the covalent modification of tyrosine hydroxylase by DA quinones. The melanin-synthetic enzyme tyrosinase in the brain may rapidly oxidize excess amounts of cytosolic DA and L-DOPA, thereby preventing slowly progressive cell damage by auto-oxidation of DA, thus maintaining DA levels. Since tyrosinase also possess catecholamine-synthesizing activity in the absence of tyrosine hydroxylase (TH), the double-edged synthesizing and oxidizing functions of tyrosinase in the dopaminergic system suggest its potential for application in the synthesis of DA, instead of TH in the degeneration of dopaminergic neurons, and in the normalization of abnormal DA turnover in long-term L-DOPA-treated Parkinson's disease patients.

[1]  E. Cadenas,et al.  Effect of superoxide dismutase on the autoxidation of various hydroquinones--a possible role of superoxide dismutase as a superoxide:semiquinone oxidoreductase. , 1988, Free radical biology & medicine.

[2]  C. Welch,et al.  Human Class Mu Glutathione Transferases, in Particular Isoenzyme M2-2, Catalyze Detoxication of the Dopamine Metabolite Aminochrome* , 1997, The Journal of Biological Chemistry.

[3]  J. Bermak,et al.  Evidence for non‐oxidative dopamine cytotoxicity: potent activation of NF‐κ B and lack of protection by anti‐oxidants , 2001, Journal of neurochemistry.

[4]  D. Metodiewa,et al.  Reactive oxygen species and reactive nitrogen species: Relevance to cyto(neuro)toxic events and neurologic disorders. An overview , 1999, Neurotoxicity Research.

[5]  L. Greene,et al.  Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[6]  M. Asanuma,et al.  Scavenging Effects of Dopamine Agonists on Nitric Oxide Radicals , 1996, Journal of neurochemistry.

[7]  Alberto Gatti,et al.  The absolute concentration of nigral neuromelanin, assayed by a new sensitive method, increases throughout the life and is dramatically decreased in Parkinson's disease , 2002, FEBS letters.

[8]  S. Fujisawa,et al.  Induction of apoptosis by dopamine in human oral tumor cell lines. , 2000, Anticancer research.

[9]  J. Smythies The neurotoxicity of glutamate, dopamine, iron and reactive oxygen species: Functional interrelationships in health and disease: A review — discussion , 1999, Neurotoxicity Research.

[10]  T. Sarna,et al.  Tyrosinase-catalyzed oxidation of dopa and related catechol(amine)s: a kinetic electron spin resonance investigation using spin-stabilization and spin label oximetry. , 1987, Biochimica et biophysica acta.

[11]  Peter T. Lansbury,et al.  Kinetic Stabilization of the α-Synuclein Protofibril by a Dopamine-α-Synuclein Adduct , 2001, Science.

[12]  J. Segura-Aguilar,et al.  On the mechanism of the Mn3(+)-induced neurotoxicity of dopamine:prevention of quinone-derived oxygen toxicity by DT diaphorase and superoxide dismutase. , 1989, Chemico-biological interactions.

[13]  M. LaVoie,et al.  Dopamine Quinone Formation and Protein Modification Associated with the Striatal Neurotoxicity of Methamphetamine: Evidence against a Role for Extracellular Dopamine , 1999, The Journal of Neuroscience.

[14]  P. Riederer,et al.  Iron‐Melanin Interaction and Lipid Peroxidation: Implications for Parkinson's Disease , 1991, Journal of neurochemistry.

[15]  MoonHee Lee,et al.  Effect of the overexpression of wild‐type or mutant α‐synuclein on cell susceptibility to insult , 2001 .

[16]  A. Björklund,et al.  Parkinson-Like Neurodegeneration Induced by Targeted Overexpression of α-Synuclein in the Nigrostriatal System , 2002, The Journal of Neuroscience.

[17]  K. Wakamatsu,et al.  Cysteinyldopamine is not incorporated into neuromelanin , 1991, Neuroscience Letters.

[18]  C. Carter,et al.  Aspirin and Salicylate Protect Against MPTP‐Induced Dopamine Depletion in Mice , 1998, Journal of neurochemistry.

[19]  M. Zigmond,et al.  Modification of Dopamine Transporter Function: Effect of Reactive Oxygen Species and Dopamine , 1996, Journal of neurochemistry.

[20]  H. M. Geller,et al.  l‐DOPA Cytotoxicity to PC12 Cells in Culture Is via Its Autoxidation , 1995, Journal of neurochemistry.

[21]  R. Kostrzewa Selective neurotoxins, chemical tools to probe the mind: The first Thirty years and beyond , 1999, Neurotoxicity Research.

[22]  K. Vrana,et al.  Dopamine, in the presence of tyrosinase, covalently modifies and inactivates tyrosine hydroxylase , 1998, Journal of neuroscience research.

[23]  J. Townsend,et al.  Pre- and Postsynaptic Neurotoxic Effects of Dopamine Demonstrated by Intrastriatal Injection , 1993, Experimental Neurology.

[24]  Barry Halliwell,et al.  Reactive Oxygen Species and the Central Nervous System , 1992, Journal of neurochemistry.

[25]  A. Aguzzi,et al.  Tyrosinase is a new marker for cell populations in the mouse neural tube. , 1995, Developmental dynamics : an official publication of the American Association of Anatomists.

[26]  L. Elferink,et al.  Tyrosine Hydroxylase Is Inactivated by Catechol‐Quinones and Converted to a Redox‐Cycling Quinoprotein , 1999, Journal of neurochemistry.

[27]  R. Coccia,et al.  Catecholamines oxidation by xanthine oxidase. , 1997, Biochimica et biophysica acta.

[28]  H. M. Swartz,et al.  Total and paramagnetic metals in human substantia nigra and its neuromelanin , 1993, Journal of neural transmission. Parkinson's disease and dementia section.

[29]  D. Tse,et al.  Potential oxidative pathways of brain catecholamines. , 1976, Journal of medicinal chemistry.

[30]  L. Chia,et al.  Elevated 5-S-cysteinyldopamine/homovanillic acid ratio and reduced homovanillic acid in cerebrospinal fluid: possible markers for and potential insights into the pathoetiology of Parkinson's disease , 2005, Journal of Neural Transmission.

[31]  A. Carlsson,et al.  Occurrence and distribution of 5-S-cysteinyl derivatives of dopamine, dopa and dopac in the brains of eight mammalian species , 1986, Neuropharmacology.

[32]  P. Lansbury,et al.  Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. , 2001, Biochemistry.

[33]  W. Damerau,et al.  Protection of melanoma cells against superoxide radicals by melanins , 2004, Journal of Cancer Research and Clinical Oncology.

[34]  The Pathogenesis of Parkinson's Disease. , 1963, Canadian Medical Association journal.

[35]  A. Korczyn Drug treatment of Parkinson's disease , 2004, Dialogues in clinical neuroscience.

[36]  G. Dryhurst,et al.  Irreversible Inhibition of Mitochondrial Complex I by 7‐(2‐Aminoethyl)‐3,4‐Dihydro‐5‐Hydroxy‐2H‐1,4‐Benzothiazine‐3‐Carboxylic Acid (DHBT‐1): A Putative Nigral Endotoxin of Relevance to Parkinson's Disease , 1997, Journal of neurochemistry.

[37]  M. Asanuma,et al.  The dopamine agonist cabergoline provides neuroprotection by activation of the glutathione system and scavenging free radicals , 2002, Neuroscience Research.

[38]  M. Kohno,et al.  Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro , 1994, Brain Research.

[39]  S. Ito,et al.  Does tyrosinase exist in neuromelanin-pigmented neurons in the human substantia nigra? , 1998, Neuroscience Letters.

[40]  K. Marcelain,et al.  Copper neurotoxicity is dependent on dopamine‐mediated copper uptake and one‐electron reduction of aminochrome in a rat substantia nigra neuronal cell line , 2001, Journal of neurochemistry.

[41]  Y. Agid,et al.  Is the Vulnerability of Neurons in the Substantia Nigra of Patients with Parkinson's Disease Related to Their Neuromelanin Content? , 1992, Journal of neurochemistry.

[42]  F Beermann,et al.  New evidence for presence of tyrosinase in substantia nigra, forebrain and midbrain. , 1998, Brain research. Molecular brain research.

[43]  J. Um,et al.  Antiapoptotic role of NF‐κB in the auto‐oxidized dopamine‐induced apoptosis of PC12 cells , 2001, Journal of neurochemistry.

[44]  A H Stokes,et al.  Tyrosinase mRNA is expressed in human substantia nigra. , 1997, Brain research. Molecular brain research.

[45]  T. Sarna,et al.  The effect of melanin on iron associated decomposition of hydrogen peroxide. , 1988, Free radical biology & medicine.

[46]  C. Mytilineou,et al.  Toxic and Protective Effects of l‐DOPA on Mesencephalic Cell Cultures , 1993, Journal of neurochemistry.

[47]  R. Kostrzewa,et al.  Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease , 2002, Amino Acids.

[48]  D. Sulzer,et al.  Intraneuronal dopamine-quinone synthesis: A review , 1999, Neurotoxicity Research.

[49]  M. Asanuma,et al.  Inhibition of Tyrosinase Reduces Cell Viability in Catecholaminergic Neuronal Cells , 2000, Journal of neurochemistry.

[50]  M. Miranda,et al.  Harding-passey mouse-melanoma tyrosinase inactivation by reaction products and activation by L-epinephrine. , 1983, General pharmacology.

[51]  T. Sarna,et al.  Antioxidant action of neuromelanin: the mechanism of inhibitory effect on lipid peroxidation. , 1995, Archives of biochemistry and biophysics.

[52]  K. Mizukawa,et al.  Degeneration of dopaminergic neurons and free radicals. Possible participation of levodopa. , 1993, Advances in neurology.

[53]  T. Sarna,et al.  The effect of a synthetic neuromelanin on yield of free hydroxyl radicals generated in model systems. , 1995, Biochimica et biophysica acta.

[54]  Sarah J. Tabrizi,et al.  Expression of mutant α-synuclein causes increased susceptibility to dopamine toxicity , 2000 .

[55]  Mitsutoshi Yamamoto,et al.  Differential effects of chronic l-DOPA treatment on lipid peroxidation in the mouse brain with or without pretreatment with 6-hydroxydopamine , 1994, Neuroscience Letters.

[56]  M. Asanuma,et al.  Apoptosis-inducing neurotoxicity of dopamine and its metabolites via reactive quinone generation in neuroblastoma cells. , 2003, Biochimica et biophysica acta.

[57]  D. Dexter,et al.  Evaluation of the pro-oxidant and antioxidant actions of L-DOPA and dopamine in vitro: implications for Parkinson's disease. , 1996, Free radical research.

[58]  I. Ziv,et al.  Prevention of Dopamine-Induced Cell Death by Thiol Antioxidants: Possible Implications for Treatment of Parkinson's Disease , 1996, Experimental Neurology.

[59]  C. Welch,et al.  Metabolic activation of dopamine o-quinones to o-semiquinones by NADPH cytochrome P450 reductase may play an important role in oxidative stress and apoptotic effects. , 1998, Biochimica et biophysica acta.

[60]  M. Zigmond,et al.  Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[61]  D. Jacobowitz,et al.  Pharmacological actions of 6-hydroxydopamine. , 1974, Pharmacological reviews.

[62]  V. Hearing,et al.  Mammalian tyrosinase. A comparison of tyrosine hydroxylation and melanin formation. , 1976, The Biochemical journal.

[63]  W. Freed,et al.  Bromocriptine Protects Dopaminergic Neurons from Levodopa-Induced Toxicity by Stimulating D2Receptors , 1999, Experimental Neurology.

[64]  R. Kostrzewa,et al.  Dopaminergic denervation enhances susceptibility to hydroxyl radicals in rat neostriatum , 2000, Amino Acids.

[65]  Fujita Keisuke,et al.  Conjugation of dopa and 5-S-cysteinyldopa with cysteine mediated by superoxide radical. , 1982 .

[66]  D. Casper,et al.  Ibuprofen protects dopaminergic neurons against glutamate toxicity in vitro , 2000, Neuroscience Letters.

[67]  L. Mosca,et al.  Lipoxygenase-catalyzed oxidation of catecholamines. , 1994, Biochemical and biophysical research communications.

[68]  M. Asanuma,et al.  Pergolide scavenges both hydroxyl and nitric oxide free radicals in vitro and inhibits lipid peroxidation in different regions of the rat brain , 1998, Brain Research.

[69]  I. Kanazawa,et al.  Repeated l-DOPA administration reduces the ability of dopamine storage and abolishes the supersensitivity of dopamine receptors in the striatum of intact rat , 1993, Neuroscience Research.

[70]  M. Asanuma,et al.  Bromocriptine Markedly Suppresses Levodopa-Induced Abnormal Increase of Dopamine Turnover in the Parkinsonian Striatum , 2000, Neurochemical Research.

[71]  K. Lange,et al.  Pathogenesis of Parkinson's disease. , 1992, Current opinion in neurology and neurosurgery.

[72]  U. Ungerstedt,et al.  6-Hydroxy-dopamine induced degeneration of central monoamine neurons. , 1968, European journal of pharmacology.

[73]  S. Berman,et al.  Dopamine Oxidation Alters Mitochondrial Respiration and Induces Permeability Transition in Brain Mitochondria , 1999, Journal of neurochemistry.

[74]  M. Kohno,et al.  Neuroprotective effects of non‐steroidal anti‐inflammatory drugs by direct scavenging of nitric oxide radicals , 2001, Journal of neurochemistry.

[75]  F. Amicarelli,et al.  Liposome-entrapped tyrosinase: a tool to investigate the regulation of the Raper-Mason pathway. , 1988, Biochimica et biophysica acta.

[76]  B. Ferger,et al.  Inhibition of the cyclooxygenase isoenzymes COX‐1 and COX‐2 provide neuroprotection in the MPTP‐mouse model of Parkinson's disease , 2001, Synapse.

[77]  D. Radice,et al.  Iron and Other Metals in Neuromelanin, Substantia Nigra, and Putamen of Human Brain , 1994, Journal of neurochemistry.

[78]  Pico Caroni,et al.  Neuropathology in Mice Expressing Human α-Synuclein , 2000, The Journal of Neuroscience.

[79]  C. Rice-Evans,et al.  Inhibition of Peroxynitrite‐Mediated Oxidation of Dopamine by Flavonoid and Phenolic Antioxidants and Their Structural Relationships , 1999, Journal of neurochemistry.

[80]  John Hardy,et al.  The A53T α-Synuclein Mutation Increases Iron-Dependent Aggregation and Toxicity , 2000, The Journal of Neuroscience.

[81]  M. LaVoie,et al.  Peroxynitrite‐ and Nitrite‐Induced Oxidation of Dopamine : Implications for Nitric Oxide in Dopaminergic Cell Loss , 1999, Journal of neurochemistry.

[82]  K. Fujita,et al.  Conjugation of dopa and 5-S-cysteinyldopa with cysteine mediated by superoxide radical. , 1982, Biochemical pharmacology.

[83]  D. Graham Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. , 1978, Molecular pharmacology.

[84]  P. Lansbury,et al.  Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[85]  S. Fahn,et al.  Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity , 1993, Annals of neurology.

[86]  N. Ogawa,et al.  Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist , 1999, Brain Research.

[87]  A. Lees,et al.  Conjugates of Catecholamines with Cysteine and GSH in Parkinson's Disease: Possible Mechanisms of Formation Involving Reactive Oxygen Species , 1998, Journal of neurochemistry.

[88]  Story C. Landis,et al.  Catecholamine Synthesis is Mediated by Tyrosinase in the Absence of Tyrosine Hydroxylase , 1999, The Journal of Neuroscience.

[89]  J. Segura-Aguilar,et al.  Behavioral effects of aminochrome and dopachrome injected in the rat substantia nigra , 2002, Pharmacology Biochemistry and Behavior.

[90]  B. Mannervik,et al.  Glutathione transferases catalyse the detoxication of oxidized metabolites (o-quinones) of catecholamines and may serve as an antioxidant system preventing degenerative cellular processes. , 1997, The Biochemical journal.

[91]  M. Kawai,et al.  Protective effects of pergolide on dopamine levels in the 6-hydroxydopamine-lesioned mouse brain. , 1995, Archives internationales de pharmacodynamie et de therapie.

[92]  J. Segura-Aguilar,et al.  Superoxide dismutase and catalase enhance autoxidation during one-electron reduction of aminochrome by NADPH-cytochrome P-450 reductase. , 1995, Biochemical and molecular medicine.

[93]  V. Hearing,et al.  Neurotoxicity due to o-Quinones: Neuromelanin formation and possible mechanisms for o-Quinone detoxification , 1999, Neurotoxicity Research.

[94]  S. Hirai,et al.  Inhibitory effects of bromocriptine on phospholipid peroxidation induced by DOPA and iron , 1995, Neuroscience Letters.

[95]  M. Mena,et al.  l‐DOPA Inhibits Complex IV of the Electron Transport Chain in Catecholamine‐Rich Human Neuroblastoma NB69 Cells , 1995, Journal of neurochemistry.

[96]  H. M. Swartz,et al.  Interaction of neuromelanin and iron in substantia nigra and other areas of human brain , 1996, Neuroscience.

[97]  R. Strong,et al.  Prostaglandin H Synthetase‐Mediated Metabolism of Dopamine: Implication for Parkinson's Disease , 1995, Journal of neurochemistry.

[98]  G. Cohen,et al.  6-Hydroxydopamine: Evidence for Superoxide Radical as an Oxidative Intermediate , 1973, Science.

[99]  M. Hahne,et al.  Tyrosinase, the key enzyme in melanin synthesis, is expressed in murine brain. , 1996, European journal of biochemistry.

[100]  M. Mena,et al.  Toxic effects of L-DOPA on mesencephalic cell cultures: protection with antioxidants , 1995, Brain Research.

[101]  J. Cadet,et al.  Long-term behavioral and biochemical effects of 6-hydroxydopamine injections in rat caudate-putamen , 1991, Brain Research Bulletin.

[102]  S Fahn,et al.  Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA. , 1999, Archives of neurology.

[103]  J. Trojanowski,et al.  Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. , 2000, Science.

[104]  M. Colado,et al.  Studies on the role of dopamine in the degeneration of 5‐HT nerve endings in the brain of Dark Agouti rats following 3,4‐methylenedioxymethamphetamine (MDMA or ‘ecstasy’) administration , 1999, British journal of pharmacology.

[105]  A. Bonfigli,et al.  Tyrosinase-like activity in normal human substantia nigra. , 1984, General pharmacology.

[106]  G. Cohen,et al.  The generation of hydrogen peroxide, superoxide radical, and hydroxyl radical by 6-hydroxydopamine, dialuric acid, and related cytotoxic agents. , 1974, The Journal of biological chemistry.

[107]  P. Riederer,et al.  Structural Characteristics of Human Substantia Nigra Neuromelanin and Synthetic Dopamine Melanins , 2000, Journal of neurochemistry.

[108]  W. H. Oertel,et al.  Salicylate protects against MPTP-induced impairments in dopaminergic neurotransmission at the striatal and nigral level in mice , 1999, Naunyn-Schmiedeberg's Archives of Pharmacology.

[109]  M. Schultzberg,et al.  Distribution of dt diaphorase in the rat brain: Biochemical and immunohistochemical studies , 1988, Neuroscience.

[110]  F. Beermann,et al.  Regulation of the tyrosinase promoter in transgenic mice: expression of a tyrosinase-lacZ fusion gene in embryonic and adult brain. , 1997, Pigment cell research.

[111]  C. Waters,et al.  Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson's disease. , 1995, The Journal of clinical investigation.

[112]  T. Hastings Enzymatic Oxidation of Dopamine: The Role of Prostaglandin H Synthase , 1995, Journal of neurochemistry.

[113]  F. L. Muiswinkel,et al.  Drug treatment of Parkinson's disease. Time for phase II. , 2000, Biochemical pharmacology.

[114]  Bruce A. Yankner,et al.  Dopamine-dependent neurotoxicity of α-synuclein: A mechanism for selective neurodegeneration in Parkinson disease , 2002, Nature Medicine.